Christine Pellegrino

Phase II Trial of Saracatinib (AZD0530), an Oral SRC-inhibitor for the Treatment of Patients with Hormone Receptor-negative Metastatic Breast Cancer

Ayca Gucalp, Joseph A. Sparano, James F. Caravelli et al. · Clinical Breast Cancer · 2011 · 159 citations · Full text

Medicine, Oncology, Pharmacology +13

Phase II Trial of Tipifarnib plus Neoadjuvant Doxorubicin-Cyclophosphamide in Patients with Clinical Stage IIB-IIIC Breast Cancer

Joseph A. Sparano, Stacy L. Moulder, Aslamuzzaman Kazi et al. · Clinical Cancer Research · 2009 · 74 citations · Full text

Medicine, Oncology, Pharmacology +17

Molecular Identification and Expression of Erythroid K:Cl Cotransporter in Human and Mouse Erythroleukemic Cells

Christine Pellegrino, Anne C. Rybicki, Sylvia Musto et al. · Blood Cells Molecules and Diseases · 1998 · 73 citations

Life Sciences, Cell Biology, Molecular Biology +5

Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy

Linda T. Vahdat, Agustin A. García, Charles L. Vogel et al. · Breast Cancer Research and Treatment · 2013 · 67 citations · Full text

Medicine, Oncology, Pharmacology +16

Targeted Inhibition of Farnesyltransferase in Locally Advanced Breast Cancer: A Phase I and II Trial of Tipifarnib Plus Dose-Dense Doxorubicin and Cyclophosphamide

Joseph A. Sparano, Stacy L. Moulder, Aslamuzzaman Kazi et al. · Journal of Clinical Oncology · 2006 · 66 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17